Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Analyst Ratings
Moderate Buy
8 Buy
7 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLTX Stock 12 Month Forecast
Average Price Target
$17.33
▲(145.47% Upside)
| Highest Price Target$65.00 | Average Price Target$17.33 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
―
Hold
―
Downgraded
10/02/25
Leerink Partners
$73→$14
Buy
98.30%
Upside
Reiterated
09/30/25
Needham
$66→$20
Buy
183.29%
Upside
Reiterated
09/30/25
Jefferies
$8
Hold
13.31%
Upside
Downgraded
09/30/25
Goldman Sachs
$7
Hold
-0.85%
Downside
Downgraded
09/30/25
Citi
$72→$5
Buy
-29.18%
Downside
Upgraded
09/30/25
LifeSci Capital
$75→$16
Buy
126.63%
Upside
Reiterated
09/29/25
BTIG
―
Hold
―
Downgraded
09/29/25
Guggenheim
$80→$20
Buy
183.29%
Upside
Reiterated
09/29/25
Wolfe Research
―
Sell
―
Downgraded
09/29/25
Wedbush
$80→$18
Buy
154.96%
Upside
Reiterated
09/29/25
Clear Street
$108→$12
Buy
69.97%
Upside
Reiterated
09/29/25
Stifel Nicolaus
$77→$13
Hold
84.14%
Upside
Downgraded
09/28/25
RBC Capital
$67→$10
Hold
41.64%
Upside
Downgraded
09/28/25
TD Cowen
―
Buy
―
Reiterated
08/05/25
We recently discussed sonelokimab with a number of HS KOLs (note here). The KOLs are optimistic about sonelokimab, and expect the pivotal trial to be positive, with sonelokimab producing a competitive profile. Based on the high unmet need and the heterogenous nature of the disease, they expect it to be adopted into the treatment paradigm and see value in having multiple options even within a drug class.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
―
Hold
―
Downgraded
10/02/25
Leerink Partners
$73→$14
Buy
98.30%
Upside
Reiterated
09/30/25
Needham
$66→$20
Buy
183.29%
Upside
Reiterated
09/30/25
Jefferies
$8
Hold
13.31%
Upside
Downgraded
09/30/25
Goldman Sachs
$7
Hold
-0.85%
Downside
Downgraded
09/30/25
Citi
$72→$5
Buy
-29.18%
Downside
Upgraded
09/30/25
LifeSci Capital
$75→$16
Buy
126.63%
Upside
Reiterated
09/29/25
BTIG
―
Hold
―
Downgraded
09/29/25
Guggenheim
$80→$20
Buy
183.29%
Upside
Reiterated
09/29/25
Wolfe Research
―
Sell
―
Downgraded
09/29/25
Wedbush
$80→$18
Buy
154.96%
Upside
Reiterated
09/29/25
Clear Street
$108→$12
Buy
69.97%
Upside
Reiterated
09/29/25
Stifel Nicolaus
$77→$13
Hold
84.14%
Upside
Downgraded
09/28/25
RBC Capital
$67→$10
Hold
41.64%
Upside
Downgraded
09/28/25
TD Cowen
―
Buy
―
Reiterated
08/05/25
We recently discussed sonelokimab with a number of HS KOLs (note here). The KOLs are optimistic about sonelokimab, and expect the pivotal trial to be positive, with sonelokimab producing a competitive profile. Based on the high unmet need and the heterogenous nature of the disease, they expect it to be adopted into the treatment paradigm and see value in having multiple options even within a drug class.
Best Analysts Covering MoonLake Immunotherapeutics
1 Month
xxx
Success Rate
15/25 ratings generated profit
Average Return
+11.94%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +11.94% per trade.
3 Months
xxx
Success Rate
18/25 ratings generated profit
Average Return
+34.03%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +34.03% per trade.
1 Year
Success Rate
9/11 ratings generated profit
Average Return
+82.16%
reiterated a buy rating 2 months ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +82.16% per trade.
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+74.75%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +74.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MLTX Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
18
19
13
8
9
Buy
4
4
6
13
14
Hold
0
0
1
1
4
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
22
23
20
22
28
Each month's total comprises the sum of three months' worth of ratings.
MLTX Financial Forecast
MLTX Stock Forecast FAQ
What is MLTX’s average 12-month price target, according to analysts?
Based on analyst ratings, MoonLake Immunotherapeutics’s 12-month average price target is 17.33.
What is MLTX’s upside potential, based on the analysts’ average price target?
MoonLake Immunotherapeutics has 145.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLTX a Buy, Sell or Hold?
MoonLake Immunotherapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 7 hold ratings and 1 sell ratings.
What is MoonLake Immunotherapeutics’s price target?
The average price target for MoonLake Immunotherapeutics is 17.33. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $5.00. The average price target represents 145.47% Increase from the current price of $7.06.
The highest analyst price target is $65.00 ,the lowest forecast is $5.00. The average price target represents 145.47% Increase from the current price of $7.06.
What do analysts say about MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of MLTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.